Show simple item record

dc.contributor.authorOrbegoso, C
dc.contributor.authorMarquina, G
dc.contributor.authorGeorge, A
dc.contributor.authorBanerjee, S
dc.date.accessioned2018-02-16T11:44:05Z
dc.date.issued2017-10
dc.identifier.citationExpert opinion on pharmacotherapy, 2017, 18 (15), pp. 1637 - 1648
dc.identifier.issn1465-6566
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1213
dc.identifier.eissn1744-7666
dc.identifier.doi10.1080/14656566.2017.1383384
dc.description.abstractIntroduction Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents. Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent to be incorporated in the ovarian cancer treatment landscape. Other molecules utilising different mechanisms of action to target angiogenesis have been developed, including cediranib, an oral potent inhibitor of VEGF Tyrosine Kinase Inhibitor that has demonstrated activity in both phase II and phase III studies. Areas covered: Herein we will review cediranib as well as the evidence for its use in ovarian cancer, both as monotherapy and in combination with chemotherapy, PARP inhibitors and immunotherapy. A literature search was made in PubMed and on ClinicalTrials.gov for clinical trials with cediranib. Expert opinion: The addition of cediranib for the treatment of ovarian cancer is promising, and has demonstrated a significant improvement in progression free survival in a phase III trial in combination with chemotherapy and maintenance treatment. Cediranib is currently being explored in ovarian cancer and other gynaecological malignancies aiming to improve patient care; further research will help define its role in standard clinical practice for patients with ovarian cancer.
dc.formatPrint
dc.format.extent1637 - 1648
dc.languageeng
dc.language.isoeng
dc.subjectAnimals
dc.subjectHumans
dc.subjectOvarian Neoplasms
dc.subjectQuinazolines
dc.subjectAngiogenesis Inhibitors
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectCombined Modality Therapy
dc.subjectDrug Evaluation, Preclinical
dc.subjectFemale
dc.subjectClinical Trials, Phase III as Topic
dc.titleThe role of Cediranib in ovarian cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14656566.2017.1383384
rioxxterms.licenseref.startdate2017-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfExpert opinion on pharmacotherapy
pubs.issue15
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.termsNot known
dc.contributor.icrauthorBanerjee, Susanaen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record